Mod GRF 1-29 & Ipamorelin Blend (10mg)

Description

The Ipamorelin peptide has been studied for its potential as a potent and efficient peptide, is a synthetic analog of human growth hormone (hGH) composed of five amino acids. Modified GRF (1-29) peptide, also known as Mod GRF 1-29, is another potentially potent and efficient peptide and is a synthetic analog of endogenous growth hormone-releasing hormones (GHRH). Composed of 29 amino acids, it has few modifications compared to the endogenous GHRH – it has four amino groups that more stable groups substitute – hence it is named a modified GRF 1-29.⁽¹⁾ Upon intake, both these peptides appear to stimulate the pituitary gland and trigger the release of growth hormones in the body. When administered together as a blend, these peptides appear to yield better, synergistic results and may produce additional benefits such as anti-aging effects, improved bone density, better sleep cycle, and overall positive effects on intestine and cardiac health. The key benefit of this peptide blend may be that Ipamorelin appears to be a fast-acting peptide with a short half-life, whereas Mod GRF 1-29 may have longer-lasting effects. So when taken together, the effects of Ipamorelin begin faster, and soon as it starts to wean off the effects of Mod GRF 1-29 peptide may kick in – yielding potentially longer-lasting results. 

Mod GRF 1-29 & Ipamorelin Chemical Makeup ^{(1) (2) (3)}

Molecular formula: Modified GRF 1-29 peptide: C₁₅₂H₂₅₂N₄₄O₄₂, Ipamorelin: C₃₈H₄₉N₉O⁽⁵⁾
Molecular weight: Modified GRF 1-29 peptide: 3367.9 g/mol, Ipamorelin: 711.9 g/mol
Other known titles: Modified GRF 1-29 peptide: CJC 1295 Without DAC, Mod GRF (1-29). Ipamorelin: Ipamorelin Acetate, IPA

Mod GRF 1-29 & Ipamorelin Blend Research

Mod GRF 1-29 & Ipamorelin Blend and GSHs, GHRPs

both Mod GRF 1-29 and Ipamorelin peptides belong to the class of growth hormone secretagogues (GSHs). One study⁽⁴⁾ examined the safety and efficacy of the growth hormone secretagogues (GSHs) and growth hormone-releasing peptides (GHRPs) in human volunteers. Several candidates subjected to the GSHs were monitored for any physiological changes. As an outcome of this rigorous study, it was concluded that these peptides appeared to improve growth rates in children, increase appetite, and improve lean mass in adults. In obese candidates, these peptides were observed to stimulate a reduction in bone turnover, increased lean mass, and improved sleep cycle.  While the current studies indicate that these peptides may be well tolerated, some concerns need further examination. As per this study, these peptides “increase lean body mass, reduce fat mass, increase exercise tolerance and maximum oxygen uptake, enhance muscle strength, and improve linear growth. Long-term studies of GH administration offer conflicting results regarding its safety, which has led to strict FDA criteria for GH use.”⁽⁴⁾

Mod GRF 1-29 & Ipamorelin Blend and Research in Vitro, in Vivo 

A 1998 study⁽⁵⁾ was carried out where these growth hormone secretagogues were administered in vitro in the rat pituitary gland and in vivo in anesthetized rats and conscious swine. Results of all three studies demonstrated that these peptides are agonists of GHRP-like receptors, as they bind to these receptors and help secrete higher concentrations of growth hormone in the body. While some growth hormone secretagogues also triggered increased levels of other hormones such as cortisol and ACTH, Ipamorelin and Modified GRF 1-29 peptides appeared to exhibit selectivity towards growth hormones only, suggesting that these peptides may be particular in their functions. This supposed ability of the peptides may prove to be highly beneficial in the therapeutic world. 

Mod GRF 1-29 & Ipamorelin Blend and Clinical Studies in Healthy Subjects

In one 1999 study,⁽⁶⁾ 8 healthy male volunteers were enrolled to examine the effects of the growth hormone secretagogues at different doses. The doses were increased every 15 minutes for up to two hours. After the study was completed, the concentration of growth hormones appeared to have significantly risen throughout the study period. These results suggest that these peptides may yield highly positive and fast results concerning maintaining high growth hormone concentrations in the body.

Mod GRF 1-29 & Ipamorelin Blend and Growth Hormone Deficiency

Post 2001, there have been several rigorous studies⁽⁷⁾ conducted on individuals suffering from growth hormone deficiency. The studies conducted so far have demonstrated that:

1. These peptides may stimulate the pituitary gland to release growth hormones naturally in the body, or
2. These peptides may act on the arcuate nucleus of the hypothalamus, which triggers the secretion of growth hormones in the body.

As per Rogerio G Gondo et al., “The predominant site of action of GHSs on GH secretion has not been established. As receptors for GHSs have been identified in both pituitary and hypothalamus (24–26), it is possible that GHSs act at either or both sites.”7 Besides this apparent growth hormone release, these peptides may also increase food appetite, improve cardiac tone, and help regulate sleep. In another study,⁽⁸⁾ six children with growth hormone deficiency were administered a graded dose of growth hormone secretagogues for eight months. All children were continually monitored for episodic growth hormone secretion and toxicity levels. Within two months of peptide administration, these children appeared to exhibit an exponential spike in the concentration of growth hormones, with no toxicities reported. 

Mod GRF 1-29 & Ipamorelin Blend and Heart Rates

In this preliminary study,⁽⁹⁾ experimental rats were examined after being administered GHRH peptide analogs such as Modified GRF 1-29 peptide. The results suggested that the peptide may improve heart rate and blood pumping ability, especially after myocardial infarction. These studies also indicated that the peptide might promote heart tissue repair and enhance the ejection fraction rate. 

Mod GRF 1-29 & Ipamorelin Blend and Sleep Cycles

Researchers⁽¹⁰⁾ have suggested that a significant portion of the growth hormone secretion affects the deep non-REM sleep (NREMS) cycle daily. Administering growth hormone secretagogues such as Ipamorelin and Modified GRF 1-29 peptide appears to improve the NREMS cycle by stimulating growth hormone secretion in the body. As per Ferenc Obal Jr et al., “Mutant and transgenic animals with a defect in GHRHergic activity display permanently reduced NREMS, which cannot be reversed by means of GH supplementation. GHRH contents and mRNA levels in the hypothalamus correlate with sleep-wake activity during the diurnal cycle and sleep deprivation and recovery sleep. Stimulation of NREMS by GHRH is a hypothalamic action. GABAergic neurons in the anterior hypothalamus/preoptic region are candidates for mediating promotion of NREMS by GHRH.” While the peptides continue to demonstrate their potential benefits in humans, further clinical studies are underway. The peptides currently available in the market are for educational and research purposes only.

References

1. National Center for Biotechnology Information (2023). PubChem Compound Summary for CID 91976842, CJC1295 Without DAC. https://pubchem.ncbi.nlm.nih.gov/compound/CJC1295-Without-DAC. 
2. National Center for Biotechnology Information (2023). PubChem Compound Summary for CID 9831659, Ipamorelin.  https://pubchem.ncbi.nlm.nih.gov/compound/Ipamorelin. 
3. Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, Paradis V, van Wyk P, Pham K, Bridon DP. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005 Jul;146(7):3052-8. doi: 10.1210/en.2004-1286. Epub 2005 Apr 7. PMID: 15817669. https://pubmed.ncbi.nlm.nih.gov/15817669/ 
4. Sigalos, John T, and Alexander W Pastuszak. “The Safety and Efficacy of Growth Hormone Secretagogues.” Sexual medicine reviews vol. 6,1 (2018): 45-53. doi:10.1016/j.sxmr.2017.02.004 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5632578/ 
5. Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998 Nov;139(5):552-61. doi: 10.1530/eje.0.1390552. PMID: 9849822. https://pubmed.ncbi.nlm.nih.gov/9849822/ 
6. Gobburu, J.V.S., Agersø, H., Jusko, W.J. et al. Pharmacokinetic-Pharmacodynamic Modeling of Ipamorelin, a Growth Hormone Releasing Peptide, in Human Volunteers. Pharm Res 16, 1412–1416 (1999). https://doi.org/10.1023/A:1018955126402 
7. Rogério G. Gondo, Manuel H. Aguiar-Oliveira, César Y. Hayashida, Sergio P. A. Toledo, Neusa Abelin, Michael A. Levine, Cyril Y. Bowers, Anita H. O. Souza, Rossana M. C. Pereira, Norma L. Santos, Roberto Salvatori, Growth Hormone-Releasing Peptide-2 Stimulates GH Secretion in GH-Deficient Patients with Mutated GH-Releasing Hormone Receptor, The Journal of Clinical Endocrinology & Metabolism, Volume 86, Issue 7, 1 July 2001, Pages 3279–3283, https://doi.org/10.1210/jcem.86.7.7694 
8. Mericq V, Cassorla F, Salazar T, Avila A, Iñiguez G, Bowers CY, Merriam GR. Effects of eight months treatment with graded doses of a growth hormone (GH)-releasing peptide in GH-deficient children. J Clin Endocrinol Metab. 1998 Jul;83(7):2355-60. doi: 10.1210/jcem.83.7.4969. PMID: 9661608. https://pubmed.ncbi.nlm.nih.gov/9661608/ 
9. Schally AV, Zhang X, Cai R, Hare JM, Granata R, Bartoli M. Actions and Potential Therapeutic Applications of Growth Hormone-Releasing Hormone Agonists. Endocrinology. 2019 Jul 1;160(7):1600-1612. https://pubmed.ncbi.nlm.nih.gov/31070727/  
10. Obal F Jr, Krueger JM. GHRH and sleep. Sleep Med Rev. 2004 Oct;8(5):367-77. doi: 10.1016/j.smrv.2004.03.005. PMID: 15336237. https://pubmed.ncbi.nlm.nih.gov/15336237/ 

---

 

NOTE: These products are intended for laboratory research use only. CJC-1295 NO DAC / MOD GRF 1 29 peptide is not intended for personal use. Please review our Terms and Conditions before ordering.